Pain Treatments was Bioventus’s largest region in fiscal 2025, bringing in $248.24M of $502.10M (49%).
| Geography | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Pain Treatments | $194.83M | $197.95M | $234.94M | $248.24M | |||
| Surgical Solutions | $133.05M | $141.89M | $167.71M | $180.44M | |||
| Restorative Therapies | $127.37M | $110.02M | $104.17M | $73.42M | |||
| Total | $455.25M | $449.86M | $506.81M | $502.10M |
Bioventus brought in $502.10M from its three regions in fiscal 2025, the year ended December 31, 2025. That is less than the $568.09M it reports by segment, so these regions do not cover all of its revenue. Pain Treatments was the largest at $248.24M (49.4%), ahead of Surgical Solutions at $180.44M (35.9%) and Restorative Therapies at $73.42M (14.6%).
Compared with fiscal 2024, Surgical Solutions grew fastest, up 7.6% to $180.44M, while Restorative Therapies fell the most, down 29.5% to $73.42M.
U.S was Bioventus’s largest region in fiscal 2025, bringing in $248.24M of $279.06M (89%).
| Geography | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| U.S | $194.83M | $197.95M | $234.94M | $248.24M | |||
| International | $21.50M | $22.85M | $26.35M | $30.82M | |||
| Total | $216.33M | $220.80M | $261.29M | $279.06M |
Bioventus brought in $279.06M from its two regions in fiscal 2025, the year ended December 31, 2025. That is less than the $568.09M it reports by segment, so these regions do not cover all of its revenue. U.S was the largest at $248.24M (89.0%), ahead of International at $30.82M (11.0%).
Compared with fiscal 2024, International grew 17.0% to $30.82M and U.S grew 5.7% to $248.24M.
U.S was Bioventus’s largest segment in fiscal 2025, bringing in $502.10M of $568.09M (88%).
| Segment | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| U.S | $455.25M | $449.86M | $506.81M | $502.10M |
| International | $56.87M | $62.49M | $66.47M | $65.99M |
| Total | $512.12M | $512.35M | $573.28M | $568.09M |
Bioventus brought in $568.09M from its two segments in fiscal 2025, the year ended December 31, 2025. That was down 0.9% from $573.28M in fiscal 2024. U.S was the largest at $502.10M (88.4%), ahead of International at $65.99M (11.6%).
Compared with fiscal 2024, International fell 0.7% to $65.99M and U.S fell 0.9% to $502.10M. From fiscal 2022 to 2025, combined revenue from these segments grew from $512.12M to $568.09M, a compound annual growth rate of 3.5%. U.S's share of the total fell from 88.9% to 88.4%.
Bioventus (BVS) reports its revenue by geography and by segment. In fiscal 2025, Pain Treatments was its largest region, bringing in $248.24M (49.4% of the total), followed by Surgical Solutions at $180.44M (35.9%).
Pain Treatments was Bioventus' largest region in fiscal 2025, bringing in $248.24M, or 49.4% of the $502.10M total across its three regions.
U.S was Bioventus' largest segment in fiscal 2025, bringing in $502.10M, or 88.4% of the $568.09M total across its two segments.
Among Bioventus' regions that make up at least 2% of revenue, Surgical Solutions grew fastest in fiscal 2025, up 7.6% from $167.71M to $180.44M.
Every figure comes from Bioventus' annual financial filings, as reported. Each line keeps the name Bioventus gives it, and years follow its fiscal calendar.
Bioventus' revenue by geography goes back to fiscal 2019, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.